LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB

NCT05210621 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Ocrelizumab

Sponsor

Centre Hospitalier Universitaire de Nice